Thirty Madison Safety, Regulation & Compliance: An Independent Clinical Review

What Exactly Is Thirty Madison and How Is It Regulated?

Thirty Madison is a holding company, not a single clinical practice. It builds and acquires condition-specific D2C telehealth brands, each operating under its own affiliated medical group. That structure matters for understanding who is actually responsible for your prescription.

The United States does not have a single federal telehealth prescribing regulator. Each state medical board licenses the prescribers who write scripts for patients in that state. Thirty Madison's affiliated medical groups must maintain active licensure in every state where they accept patients, and the medications they prescribe must have FDA approval for the indicated use or, in some cases, be available as compounded alternatives through 503A/503B pharmacies.

The Affiliated Medical Group Model

Telehealth companies routinely use what the industry calls a "friendly PC" or "affiliated medical group" structure. Thirty Madison's brands rely on external physician organizations that retain clinical independence, on paper. The Federal Trade Commission and several state attorneys general have scrutinized affiliated PC arrangements across the D2C space, though as of this writing no enforcement action has been taken specifically against Thirty Madison or its subsidiaries.

The medical groups affiliated with Thirty Madison are required to follow the same standard-of-care guidelines that govern brick-and-mortar practices. For finasteride prescribing, that means adherence to American Academy of Dermatology (AAD) guidelines, which recommend a 5-alpha reductase inhibitor discussion that includes sexual side effects, potential impact on PSA levels, and the need for pregnancy avoidance in female partners [1].

State Licensing and Prescribing Reach

Keeps, the largest Thirty Madison subsidiary by patient volume, states that it serves patients in all 50 states. Maintaining prescriber licensure in all 50 states is operationally demanding and requires strong credentialing infrastructure. Patients should verify, before starting a subscription, that their specific state is actively serviced by checking the platform's current coverage map, since that list can change as prescriber contracts shift.

Keeps (Hair Loss): Safety Profile of the Core Drug Portfolio

Keeps prescribes finasteride (1 mg/day oral) and minoxidil (topical 5% and oral) for male androgenic alopecia. Both are FDA-approved for that indication. Understanding the safety profile of each drug is more clinically relevant than any brand-level review.

Finasteride 1 mg: Efficacy Is Real, but So Are the Risks

The key finasteride 1 mg trial (N=1,553 men, 12 months) demonstrated a statistically significant increase in hair count vs. Placebo and was the basis for FDA approval of Propecia in 1997 [2]. Two-year and five-year extension data confirmed sustained efficacy.

The safety conversation around finasteride is more complicated. In 2012, the FDA updated the Propecia label to include sexual side effects (decreased libido, erectile dysfunction, ejaculation disorders) that may persist after discontinuation, a cluster now referred to clinically as Post-Finasteride Syndrome (PFS) [3]. The prevalence of persistent sexual dysfunction after stopping finasteride is contested; a 2017 study in The Journal of Sexual Medicine reported persistent adverse sexual effects in roughly 1.4% of users [4], though advocacy groups argue the true rate is higher.

Keeps discloses these risks in its online intake questionnaire. Whether a brief asynchronous questionnaire constitutes adequate informed consent for a drug with this side-effect profile is a legitimate question that patients and clinicians can reasonably disagree on.

Oral Minoxidil: Growing Off-Label Use, Incomplete Safety Data

Oral minoxidil for hair loss is prescribed off-label; the FDA-approved oral minoxidil formulations are indicated for hypertension, not alopecia. The emerging evidence base is promising, a 2021 systematic review in the Journal of the American Academy of Dermatology (N=634 across 17 studies) found low-dose oral minoxidil (0.25 to 5 mg/day) effective for multiple hair-loss types with a manageable side-effect profile [5], but long-term safety data in the hair-loss population are thin.

Common side effects include hypertrichosis (unwanted facial or body hair), fluid retention, and tachycardia. Patients with pre-existing cardiovascular conditions should have a clinical evaluation before starting, and Keeps' asynchronous intake may not always capture the nuance required to flag those patients. The AAD's position statement on oral minoxidil for alopecia, published in 2022, calls for blood pressure monitoring and a baseline cardiovascular screen [1].

Topical Minoxidil: Well-Established Safety, Low Systemic Absorption

Topical minoxidil 5% (Rogaine and generics) has the longest safety record in this portfolio. Systemic absorption is low; the most common adverse events are scalp irritation and, in a minority of users, initial shedding in the first 6 to 8 weeks of use. The AAD rates topical minoxidil as a Grade A recommendation for male androgenic alopecia [1].

Cove (Migraine): Prescribing Practices and Clinical Guardrails

Cove prescribes acute migraine treatments (triptans, NSAIDs, anti-nausea agents) and preventive therapies (topiramate, propranolol, amitriptyline, and, more recently, CGRP antagonists such as rimegepant).

Triptans: Safe for Most, Contraindicated for a Meaningful Minority

Sumatriptan and related triptans are first-line acute migraine therapy per the American Headache Society [6]. They are contraindicated in patients with ischemic heart disease, uncontrolled hypertension, hemiplegic migraine, and a history of stroke. These contraindications are clinically important because migraine is more prevalent in populations with elevated cardiovascular risk.

Cove's intake asks about cardiovascular history, but a typed patient self-report is not equivalent to a resting ECG, blood pressure measurement, or physician auscultation. Patients with any cardiovascular history should discuss this directly with a Cove-affiliated prescriber via a synchronous video visit rather than relying on asynchronous intake.

Topiramate: Effective but Demands Closer Monitoring

Topiramate for migraine prevention has solid efficacy data: two key RCTs (MIGR-001 and MIGR-002, combined N~900) showed 50% responder rates of roughly 46% vs. 23% placebo [7]. The drug carries a teratogenicity risk (FDA Pregnancy Category D, now reflected in PREA labeling); the FDA requires oral contraceptive counseling for patients of childbearing potential [8]. Topiramate also reduces the efficacy of combined oral contraceptives by inducing CYP3A4.

Cove's intake questionnaire covers pregnancy intentions, but the drug-drug interaction with oral contraceptives requires explicit counseling that a short text intake may not provide adequately. Patients on OCs who are prescribed topiramate should request a direct discussion with their prescriber about backup contraception.

CGRP Antagonists: A Newer Tier with Less Longitudinal Data

Rimegepant (Nurtec ODT, FDA-approved 2020) and ubrogepant (Ubrelvy, FDA-approved 2019) are now available through some telehealth platforms including Cove. Both carry a cleaner cardiovascular contraindication profile than triptans, which is clinically meaningful for the subset of migraine patients who cannot use triptans. Long-term post-marketing safety data are still accumulating; the FDA's PREA commitments for both drugs include ongoing pediatric and safety studies [8].

Sexual Health and Skin: A Brief Overview of Remaining Brands

Thirty Madison has at various points operated or considered brands in sexual health (ED, PE) and skin care (Facet). The ED telehealth space involves prescribing sildenafil and tadalafil, both FDA-approved PDE5 inhibitors with established safety profiles, but the same asynchronous-intake concerns about cardiovascular screening apply. The ACC/AHA guidelines state that PDE5 inhibitors are contraindicated with nitrate medications and should be used cautiously in patients with low-output cardiac states [9].

Facet (personalized skincare) may include tretinoin prescribing. Tretinoin is FDA-approved for acne and is well-tolerated topically, but it is teratogenic and requires pregnancy counseling consistent with iPLEDGE-style precautions, even though it is not formally enrolled in iPLEDGE.

Is Thirty Madison Legit? Regulatory Compliance Assessment

"Legit" in a regulatory context means four things: lawful business structure, licensed prescribers, FDA-approved (or legally compounded) medications, and pharmacy compliance. Thirty Madison appears to meet all four criteria as of early 2025.

Pharmacy Partners and Drug Sourcing

Keeps and Cove dispense through NABP-accredited pharmacies. The National Association of Boards of Pharmacy (NABP) Verified Pharmacy Program is the most reliable third-party signal that a dispensing pharmacy meets federal and state standards for drug sourcing, storage, and dispensing. Patients can verify a pharmacy's NABP status at nabp.pharmacy.

No FDA Warning Letters or FTC Consent Decrees (as of publication)

As of January 2025, the FDA's warning letter database and the FTC's enforcement action log do not contain entries specifically naming Thirty Madison, Keeps, or Cove. That is a meaningful baseline, though it reflects the absence of detected violations rather than active regulatory approval of specific clinical practices.

Telehealth-Specific Compliance Risks Across the Industry

The FTC's 2023 policy statement on telehealth and subscription marketing practices called out dark patterns in cancellation flows, a category of compliance risk relevant to subscription-based telehealth companies broadly [10]. Keeps has faced user complaints on the Better Business Bureau platform regarding subscription cancellation difficulty. Those complaints are not regulatory findings, but they signal a customer-experience compliance gap that prospective patients should know about.

Thirty Madison vs. Alternatives: A Clinical Comparison

Patients evaluating Thirty Madison's brands should benchmark against both traditional care and competing telehealth platforms.

Keeps vs. Hims / Roman (Hair Loss)

All three platforms prescribe finasteride 1 mg and topical minoxidil. Hims and Roman also offer branded minoxidil formulations and, in some markets, oral minoxidil. The clinical outcomes achievable are product-driven, not platform-driven, a finasteride 1 mg tablet from Keeps and one from Hims are pharmacologically identical if dispensed correctly. Price differences do exist: Keeps' finasteride runs approximately $15, $25/month; Hims' finasteride runs approximately $20, $30/month at comparable doses. Neither platform replaces the diagnostic value of a dermatologist trichoscopy for complex cases.

Cove vs. Axon Optics / Nurx / Traditional Neurology (Migraine)

Cove's value proposition is speed of access. The American Headache Society estimates that only about 56% of migraine patients in the U.S. Have received a formal diagnosis, and access to headache neurologists is limited in rural areas [6]. For uncomplicated episodic migraine without cardiovascular risk factors, Cove's model offers a clinically reasonable path to guideline-concordant therapy. Patients with chronic migraine (15 or more headache days per month), medication-overuse headache, or prior stroke should be evaluated by a neurology specialist, not a questionnaire.

Thirty Madison vs. Direct Primary Care or Traditional Dermatology

The honest comparison: D2C telehealth trades depth of assessment for speed and cost. A board-certified dermatologist examining the scalp directly can differentiate androgenic alopecia from alopecia areata, telogen effluvium, scarring alopecia, or tinea capitis, conditions that a photo-based telehealth intake cannot reliably distinguish. Finasteride prescribed to a patient with undiagnosed alopecia areata provides no benefit and delays correct treatment.

What Thirty Madison Reviews Say, and What the Evidence Shows

Patient review aggregators (Trustpilot, BBB, Reddit communities such as r/Keeps) show a bimodal distribution: patients who respond well to finasteride and minoxidil tend to report high satisfaction after 6 to 12 months, consistent with the known efficacy timeline. Patients who experience side effects, particularly finasteride-related sexual dysfunction, report frustration with the platform's responsiveness.

The clinical takeaway from the review corpus is not surprising: satisfaction tracks with drug efficacy and tolerability, and both vary by individual pharmacogenomics and baseline risk. No review platform can substitute for pre-treatment labs, but a physician reviewing a patient's cardiovascular and hormonal history before prescribing finasteride can flag risk factors that a questionnaire misses.

Patient Safety Checklist Before Starting a Thirty Madison Subscription

Before completing intake on any Thirty Madison subsidiary, patients should consider the following steps.

1. Confirm your state is actively covered by verifying with the platform directly, not just assuming based on the website's general claims.
2. For finasteride: disclose any prior history of sexual dysfunction, depression, or low testosterone, since these may increase the risk of persistent side effects.
3. For topiramate: inform the platform prescriber of every contraceptive method in use, and ask explicitly about the OC interaction.
4. For oral minoxidil: ensure your blood pressure has been measured within the past 12 months. If you have a history of pericardial effusion, heart failure, or uncontrolled hypertension, request a synchronous video visit before starting.
5. For any subscription: document the cancellation procedure before you enter payment details. Screenshot the cancellation policy page at sign-up.

Key Safety Statistics at a Glance

The numbers below are drawn from published trials on the specific drugs in Thirty Madison's portfolio, not from Thirty Madison's own marketing.

• Finasteride 1 mg vs. Placebo at 12 months: mean 107-hair increase per 1-cm² target area vs. A decrease in the placebo group (N=1,553, P<0.001) [2].
• Topiramate 100 mg/day migraine prevention: 50% responder rate of 46.6% vs. 22.6% placebo across MIGR-001 and MIGR-002 (combined N approximately 900, P<0.001) [7].
• Low-dose oral minoxidil (0.25 to 5 mg/day): 17 studies, N=634, mean response rate of 84.6% for any hair density improvement at endpoint; serious cardiovascular events reported in <1% of study participants [5].
• Sumatriptan 100 mg: pain-free at 2 hours in approximately 32% of patients vs. 11% placebo in the original key trial [11].

The AAD's Clinical Practice Guidelines state: "Topical minoxidil applied twice daily is recommended as a first-line treatment for male androgenic alopecia (Grade A, Level of Evidence I)" [1]. The American Headache Society's 2021 consensus statement notes: "Triptans remain the most effective acute treatments for moderate-to-severe migraine in patients without cardiovascular contraindications" [6].